DCM
BMRN icon

Dupont Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Dupont Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-517
Closed -$53.5K – 808
2022
Q4 		$53.5K Sell
517
-2,649
-84% -$249K ﹤0.01% 1053
2022
Q3 		$268K Buy
3,166
+1,333
+73% +$119K 0.02% 794
2022
Q2 		$152K Buy
1,833
+507
+38% +$40.4K 0.01% 1060
2022
Q1 		$102K Buy
1,326
+42
+3% +$3.51K ﹤0.01% 1253
2021
Q4 		$113K Buy
+1,284
New +$106K ﹤0.01% 1271
2021
Q3 		– Sell
-2,190
Closed -$183K – 1729
2021
Q2 		$183K Hold
2,190
– – ﹤0.01% 1320
2021
Q1 		$165K Buy
2,190
+307
+16% +$25.1K ﹤0.01% 1301
2020
Q4 		$165K Sell
1,883
-586
-24% -$46.5K ﹤0.01% 1165
2020
Q3 		$188K Sell
2,469
-8,370
-77% -$847K ﹤0.01% 1132
2020
Q2 		$1.34M Sell
10,839
-614
-5% -$61K 0.03% 414
2020
Q1 		$968K Buy
11,453
+4,371
+62% +$377K 0.02% 463
2019
Q4 		$599K Buy
7,082
+2,135
+43% +$161K 0.01% 752
2019
Q3 		$333K Sell
4,947
-1,175
-19% -$90.5K 0.01% 955
2019
Q2 		$524K Sell
6,122
-2,469
-29% -$211K 0.01% 763
2019
Q1 		$763K Hold
8,591
– – 0.02% 618
2018
Q4 		$732K Buy
8,591
+3,542
+70% +$337K 0.02% 620
2018
Q3 		$490K Buy
+5,049
New +$504K 0.01% 721
2018
Q2 		– Sell
-1,717
Closed -$139K – 981
2018
Q1 		$139K Sell
1,717
-146
-8% -$12.5K ﹤0.01% 854
2017
Q4 		$166K Sell
1,863
-3,900
-68% -$339K ﹤0.01% 804
2017
Q3 		$536K Buy
5,763
+3,900
+209% +$345K 0.01% 665
2017
Q2 		$169K Sell
1,863
-417
-18% -$37.9K ﹤0.01% 827
2017
Q1 		$200K Hold
2,280
– – ﹤0.01% 810
2016
Q4 		$189K Buy
+2,280
New +$196K ﹤0.01% 787

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Dupont Capital Management's BMRN Position: Q1 2023 in Review

Dupont Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2023, closing a stake of 517 shares — an estimated $53.5K sold.

Dupont Capital Management first reported a position in BMRN in Q4 2016 and held it in 23 quarters. The position peaked at $1.34M in Q2 2020. 552 funds tracked by Wall St. Rank hold BMRN as of Q1 2023.

  • Dupont Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Dupont Capital Management sold 517 BioMarin Pharmaceuticals shares in Q1 2023, an estimated $53.5K.
  • Dupont Capital Management first reported a position in BioMarin Pharmaceuticals in Q4 2016 and held it in 23 quarters.
  • Dupont Capital Management's BioMarin Pharmaceuticals position peaked at $1.34M in Q2 2020.
  • 552 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2023.

Based on Dupont Capital Management's 13F filing for Q1 2023, filed 28 Apr 2023.